NR3C1 and type 2 diabetes mellitus: Nuclear receptors, such as the glucocorticoid receptor (GR), the retinoid x receptors (RXR), the peroxisomal proliferator‐activated receptor α (PPARα), and gamma (PPARγ), are targets of already approved drugs for the treatment of autoimmunity, cancer, hyperlipidemia, or type 2 diabetes [12].